Table 2.
Factors associated with high IPT rates on bivariate logistic regression analysis
| Predictor | OR (95%CI) | P value |
|---|---|---|
| Total number of health care workers | 0.13 (0.08–1.16) | 0.71 |
| Predisposing factors (clinician beliefs) | ||
| MoH recommendation for IPT under the HIV program is put into practice at the health facility | 1.02 (0.99–1.08) | 0.20 |
| IPT promotes INH resistance | 0.49 (0.13–1.77) | 0.28 |
| MDR-TB rate increases with IPT | 0.72 (0.47–1.12) | 0.14 |
| Contraindications to IPT exist | 0.13 (0.02–0.55) | 0.05 |
| IPT failure high among patients | 0.99 (0.63–1.57) | 0.99 |
| IPT side effects negatively impact patients | 0.22 (0.05–0.96) | 0.04 |
| Ruling out active TB is difficult | 0.93 (0.90–0.96) | <0.001 |
| Enabling factors | ||
| TB-HIV training ever received | 2.06 (0.65–6.52) | 0.21 |
| Updates on IPT information received from JHU-TSEHAI | 2.42 (0.81–7.24) | 0.11 |
| INH stock out in the last 3 months | 0.56 (0.19–1.65) | 0.29 |
| Guidelines confirmed on site | 2.09 (0.82–5.33) | 0.12 |
| Reinforcing factors | ||
| Supervisors have emphasized improving IPT uptake | 1.42 (0.84–2.41) | 1.91 |
| Agree IPT adherence is poor | 0.71 (0.26–1.89) | 0.50 |
OR = odds ratio; CI = confidence interval; MoH = Ministry of Health; IPT = INH preventive therapy; HIV = human immunodeficiency virus; INH = isoniazid; MDR-TB = multidrug-resistant TB; TB = tuberculosis; JHU TSEHAI = Johns Hopkins Technical Support for Ethiopian HIV/AIDS Initiative.